Brief: Intercept Receives Complete Response Letter From FDA For Obeticholic Acid As A Treatment For Pre-Cirrhotic Fibrosis Due To Nash

Intercept Pharmaceuticals

23/06/2023 12:14

June 23 (Reuters) - Intercept Pharmaceuticals Inc
 ICPT.O :
    * INTERCEPT RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
OBETICHOLIC ACID AS A TREATMENT FOR PRE-CIRRHOTIC FIBROSIS DUE
TO NASH
    * INTERCEPT PHARMACEUTICALS INC- COMPANY ANTICIPATES
ACHIEVING
PROFITABILITY IN 2024 AS A RESULT OF PLANNED ACTIONS
    * INTERCEPT PHARMACEUTICALS INC- TO DISCONTINUE ALL
NASH-RELATED
INVESTMENT AND RESTRUCTURE COMPANY'S OPERATIONS TO STRENGTHEN
ITS FOCUS ON RARE AND SERIOUS LIVER DISEASES
    * INTERCEPT PHARMACEUTICALS INC- FDA INDICATED IN CRL THAT
IT
COMPLETED ITS REVIEW OF NDA AND DETERMINED THAT IT CANNOT BE
APPROVED IN ITS PRESENT FORM

Source text for Eikon:  ID:nGNX6bxPbJ 
Further company coverage:  ICPT.O 

 ((reuters.briefs@thomsonreuters.com;))